OTC Tylenol Sales Could Shrink By Half With Acetaminophen Dose Restriction

Johnson & Johnson could lose roughly $500 million in nonprescription Tylenol sales if FDA follows an advisory committee recommendation to switch 500-g tablets of acetaminophen to Rx status

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet